COPE — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20

Clinical trials — most relevant to COPE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)	PHASE1/PHASE2	NOT_YET_RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.	PHASE1/PHASE2	RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy	EARLY_PHASE1	RECRUITING
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease	nan	COMPLETED
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application	nan	COMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia	nan	RECRUITING
Analysis of Salivary Proteins in Young Children as an Device to Improve Caries Risk Assessment	nan	RECRUITING
Brain Involvement in Dystrophinopathies Part 2	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Clinical Outcome Study for Dysferlinopathy	nan	UNKNOWN
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)	nan	RECRUITING
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam	nan	UNKNOWN
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)	nan	RECRUITING
The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.	nan	RECRUITING
MNGIE Natural History Study	nan	RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies	nan	UNKNOWN
Identification of New FTLD Genes	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a COPE binder may also engage these)

Protein	Name	Similarity
Q5RFR8	—	1.000	Q5RFR8 →
O89079	—	1.000	O89079 →
Q28104	—	1.000	Q28104 →
Q60445	—	1.000	Q60445 →
Q5ZIK9	—	1.000	Q5ZIK9 →
O64748	—	0.995	O64748 →
P0C541	—	0.991	P0C541 →
Q9MAX6	—	0.991	Q9MAX6 →
Q9SA78	—	0.990	Q9SA78 →
Q86WT1	—	0.986	Q86WT1 →
A2XY73	—	0.986	A2XY73 →
Q5M7J9	—	0.986	Q5M7J9 →
Q6WRS2	—	0.985	Q6WRS2 →
CTR9	RNA polymerase-associated protein CTR9 homolog	0.985	landscape →
Q99J38	—	0.985	Q99J38 →
Q8AVU9	—	0.985	Q8AVU9 →
Q4QQS2	—	0.984	Q4QQS2 →
Q7Z4L5	—	0.983	Q7Z4L5 →
B2RYD6	—	0.983	B2RYD6 →
Q0HA38	—	0.983	Q0HA38 →
Q8N4P2	—	0.982	Q8N4P2 →
Q5AZQ5	—	0.982	Q5AZQ5 →
A2AKQ8	—	0.982	A2AKQ8 →
A6H739	—	0.981	A6H739 →
Q4X0I8	—	0.981	Q4X0I8 →
Q62018	—	0.981	Q62018 →
A2VE45	—	0.981	A2VE45 →
Q6DEU9	—	0.981	Q6DEU9 →
Q6INU8	—	0.980	Q6INU8 →
Q2UF96	—	0.980	Q2UF96 →